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Capture reagents are critical to afﬁnity-based bioanalytical methods. The potential bias of capture re-
agents, for or against certain subpopulations of the target of interest, may lead to inaccurate quantitation.
This issue is more profound for sensitive measurements, such as post-translational modiﬁcation (PTM)
proﬁling of therapeutic proteins from complex matrix. Here, a recently developed afﬁnity puriﬁcation
coupled mass spectrometric method was utilized to assess the full sequence of a circulating therapeutic
aglycosylated IgG1 (MAB3) in human subject, using two different capture reagents. We monitored all
PTMs known to be related to MAB3 drug quality (three representative PTMs are shown in this paper). The
results validated the comparability of these two reagents.
© 2016 The Author(s). Published by Elsevier Ltd on behalf of International Alliance for Biological
Standardization. This is an open access article under the CC BY license (http://creativecommons.org/
licenses/by/4.0/).1. Introduction
Monoclonal antibody (mAb) drug development is one of the
fastest growing areas of the biopharmaceutical industry [1,2], and
pharmacokinetic (PK) study is an essential part of the process [3]. In
order to build a mechanistic PK model, it is necessary to accurately
measure therapeutic antibody concentration in complex biological
matrices, such as plasma and serum.
For such measurement, an afﬁnity-based capturing step is
usually included in bioanalytical assays (e.g., ELISA) to reduce the
matrix background interference. In particular, for therapeutic an-
tibodies, two types of capture reagents are widely used: soluble
target antigen and monoclonal anti-idiotypic (anti-id) antibody
[3,4]. Early in the discovery phase, soluble target is often used to
screen therapeutic antibody candidates from hybridoma or phage
display library, and thus, soluble target is readily available during
this stage of the development process. In contrast, anti-id antibody,
which binds speciﬁcally to the complementarity-determining re-
gion of the therapeutic antibody, must be generated after the drug
candidate is chosen. As a result, anti-id antibody may not be
immediately available. Nevertheless, anti-id antibody has severaler Ltd on behalf of International Al
.
al., Comparative study of proﬁ
ogicals (2016), http://dx.doi.oadvantages over soluble target, such as higher stability, lower cost,
less lot variability and larger production scale.
Recently, we began investigating in vivo dynamics of PTMs of
mAb drugs from biological ﬂuids to understand the impacts of
PTMs on antibody drug quality [5,6]. Antibody drug was afﬁnity
puriﬁed with capture reagent and submitted to PTM proﬁling with
liquid chromatography-mass spectrometry (LC-MS). While ELISA-
type assays only measure ball-park concentration of mAb drug,
LC-MS quantiﬁes the levels of individual PTMs, such as deamidation
and oxidation, and provides more comprehensive information. One
challenge is that, due to the low levels of many PTMs, small biases
of the capture reagent may be ampliﬁed and compromise the
quantitation of these PTMs. Despite the importance of identifying
such bias, a head-to-head comparison of these two major capture
reagents, soluble target and anti-id, has not be reported for PTM
proﬁling of antibody drugs.
In order to ﬁll up the gap of knowledge, we assessed the full
sequence and compared multiple PTM quantitation results of
circulating MAB3 in a human subject, using two capture reagents,
the soluble target and neutralizing anti-id antibody. The results
support the comparability of these two different capture reagents.
In addition, our study demonstrates the use of different capture
reagents as a way to validate the antibody drug PTM proﬁles ob-
tained from clinical samples.liance for Biological Standardization. This is an open access article under the CC BY
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2.1. Clinical sample information
A single dose of MAB3, a therapeutic aglycosylated IgG1, was
administered intravenously to the human subject. This study is a
single ascending dosage (SAD) PK study, which was conducted in
accordance with regulatory guidelines. This study was reviewed
and approved by an institutional review board in Biogen. Written
informed consents were obtained from all participants. Blood was
drawn at pre-deﬁned time points and processed into serum for
storage.
2.2. Afﬁnity puriﬁcation-LC-MS
MAB3 were afﬁnity puriﬁed from these samples with either its
soluble target or a neutralizing anti-id antibody as capture reagents
and submitted to LC-MS peptide mapping in a process similar to
our previous reports [5,6].
3. Results and discussion
MAB3 were afﬁnity puriﬁed from these samples with either its
soluble target or a neutralizing anti-id antibody as capture re-
agents (Fig. 1A). A heavy-labelled MAB3 standard was produced
for accurate absolute quantitation. In the heavy-labelled MAB3
standard, all lysine and arginine residues were substituted by their
13C and 15N containing counterparts. A constant amount of heavy-
labelled MAB3 was spiked into the samples and the ratio of “light”Fig. 1. Comparison of in vivo MAB3 concentration over time curves. A) Scheme of two afﬁn
from three surrogate peptides. C) Data with anti-id. Data were from three surrogate peptid
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quantitation [5,6]. The results indicated that these two capture
reagents are comparable to each other for absolute quantitation, as
three surrogate peptides showed overlapping in vivo concentra-
tion curves over time (Fig. 1B, C and D). The relative levels of PTMs
were also quantiﬁed. Due to the low levels of certain PTMs, such
quantitation could be more sensitive to the bias of capture reagent.
We assessed the full sequence of MAB3 (100% sequence coverage)
and quantiﬁed all PTMs known to be related to the quality of the
antibody drug (Among them, three representative PTMs are re-
ported in this paper). The overall results showed that soluble
target and neutralizing anti-id antibody performed similarly for
quantifying PTMs. Representative PTMs located in different re-
gions of MAB3 demonstrate no detectable bias between the two
capture reagents (Fig. 2).
In general, monoclonal anti-id antibody has been favored over
soluble target for traditional ELISA-type PK assays due to its sta-
bility, cost and production consistency and scalability. In this study,
we provided further evidence that neutralizing anti-id antibody
was comparable to soluble target for PTM quantitation of the
antibody drug MAB3. Further studies are needed to test whether
this conclusion can be generalized for all antibody drugs. It is also
worth noting that neutralizing anti-id and soluble target may suffer
the same biases because they bind to similar regions of the anti-
body drug. When resources and timelines allow, multiple afﬁnity
reagents against different parts of the antibody drug may provide
the most comprehensive results. Polyclonal anti-id antibody may
satisfy such criteria, but inconsistency of product lots and cross-
reactivity are common problems with this class of reagents. It isity puriﬁcation approaches. B) Data with soluble target as capture reagent. Data were
es. D) Overlay of the averaged concentrations of three peptides.
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Fig. 2. Comparison of relative levels of representative PTMs. A) Hydroxylation at a lysine in variable domain; B) A deamidation site on Fc domain; C) Pyroglutamate at the heavy
chain N-terminus.
Y. Zhang et al. / Biologicals xxx (2016) 1e3 3conceivable that a deﬁned mixture of several recombinant afﬁnity
reagents that bind to distinct regions of therapeutic proteins may
be a desirable alternative.
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